CN113925867A - Application of dronedarone hydrochloride and 5-fluorouracil in preparation of antitumor drugs - Google Patents
Application of dronedarone hydrochloride and 5-fluorouracil in preparation of antitumor drugs Download PDFInfo
- Publication number
- CN113925867A CN113925867A CN202111393977.0A CN202111393977A CN113925867A CN 113925867 A CN113925867 A CN 113925867A CN 202111393977 A CN202111393977 A CN 202111393977A CN 113925867 A CN113925867 A CN 113925867A
- Authority
- CN
- China
- Prior art keywords
- fluorouracil
- dronedarone hydrochloride
- liver cancer
- lung cancer
- hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses application of dronedarone hydrochloride and 5-fluorouracil in preparation of antitumor drugs, and pharmacodynamic experiments prove that dronedarone hydrochloride and 5-fluorouracil can effectively inhibit proliferation of human hepatoma cell strains HepG2, PLC/PRF/5 and Hep 3B. The dronedarone hydrochloride can be used alone to effectively inhibit the proliferation of human liver cancer cell strains HepG2, PLC/PRF/5 and Hep3B, and the dronedarone hydrochloride can be used alone to effectively inhibit the proliferation of human lung cancer cell lines SPC-A1 and A549 and mouse lung cancer cell lines Lewis. In addition, the combination of dronedarone hydrochloride and 5-fluorouracil can inhibit the growth of tumors in a mouse liver cancer transplantation tumor model. The dronedarone hydrochloride and antitumor drug has the characteristics of safety, effectiveness and the like when being used for treating liver cancer and lung cancer, can be used for preparing the drugs for treating the liver cancer and the lung cancer, and provides a new treatment strategy for clinically treating the liver cancer and the lung cancer.
Description
Technical Field
The invention relates to the field of biological medicines, in particular to application of dronedarone hydrochloride and 5-fluorouracil in preparation of a medicine for treating liver cancer and lung cancer.
Background
Liver cancer is a common malignant tumor of digestive system, and Chinese liver cancer patients account for about half of the whole world. There are about 84.1 ten thousand new liver cancer patients and 78.2 ten thousand dead liver cancer patients each year. China is a big liver cancer country, the incidence rate of liver cancer in China is 26.92/10 ten thousand, and the death rate is 23.72/10 ten thousand. The morbidity and mortality of liver cancer are ranked the fourth and the second in malignant tumors in our country, respectively. Liver cancer has the characteristics of difficult early diagnosis, rapid progress, poorer prognosis and the like, the overall five-year survival rate of liver cancer in China is only 12.5 percent, and the life and health of people in China are seriously threatened. At present, radiation therapy and chemotherapy are mainly used for preventing postoperative recurrence of esophageal cancer, but serious side effects brought to a body after radiation therapy and chemotherapy enable radiotherapy and chemotherapy to extend the life of a patient and also aggravate adverse conditions of prognosis of the patient. And the 5-year survival rate of the liver cancer patient is still not obviously improved. Lung cancer is the most globally prevalent malignancy, accounting for the first in men and women, and the second in women. Although surgical resection and effective assistance are effective in early stage of the disease, lung cancer is still a large cancer threatening the life and health of patients due to poor prognosis and low early diagnosis rate of patients and serious side effects of radiotherapy and chemotherapy to the body. Therefore, there is an urgent need to find new therapeutic means for treating liver cancer and lung cancer.
Dronedarone hydrochloride is a drug for treating arrhythmia, and has the chemical name of N- (2-butyl-3- (4- (3-dibutylaminopropoxy) benzoyl) benzofuran-5-yl) methanesulfonamide hydrochloride. The Chinese name is Dronedarone Hydrochloride, the English name is Dronedarone Hydrochloride, the CAS registry number is 141625-93-6, and the molecular weight is 593.22. The pharmacological action of the compound is similar to that of amiodarone, and dronedarone hydrochloride is also a multichannel inhibitor and has blocking effect on sodium, potassium and calcium ion channels, beta receptors and the like. Dronedarone hydrochloride can prolong the action potential time course of cardiac muscle, slow down the atrioventricular conduction rate and slow down sinus rhythm; meanwhile, the composition has an obvious negative muscle force effect, can increase the left ventricular diastolic pressure under the condition of unchanged cardiac output, but does not change the left ventricular ejection fraction or shorten the fraction. 5-fluorouracil is mainly used for treating digestive tract tumors clinically, or fluorouracil is used for treating choriocarcinoma with larger dose. It is also used for treating breast cancer, ovarian cancer, lung cancer, cervical cancer, bladder cancer, skin cancer, etc.
Disclosure of Invention
The invention aims to provide a new combined medicine for treating liver cancer and lung cancer, and a new application of dronedarone hydrochloride and 5-fluorouracil in preparing antitumor drugs, provides a new scheme for clinically treating liver cancer and lung cancer, can reduce the dosage of dronedarone hydrochloride and 5-fluorouracil, improves the antitumor effect of dronedarone hydrochloride and 5-fluorouracil, and reduces toxic and side effects.
In order to achieve the purpose, the invention adopts the technical scheme that the dronedarone hydrochloride and 5-fluorouracil are combined to prepare the antitumor drug, and the antitumor drug is a drug for treating liver cancer and/or lung cancer.
Furthermore, the dosage form of the anti-tumor medicament comprises any one pharmaceutically acceptable dosage form.
Preferably, the dosage form includes an oral dosage form and an injectable dosage form.
Further, the two separate formulations of dronedarone hydrochloride and 5-fluorouracil are administered simultaneously or the two separate formulations are administered sequentially.
Preferably, the dosage of the dronedarone hydrochloride is 20 mg/kg/day to 100 mg/kg/day, and the dosage of the 5-fluorouracil is 20 mg/kg/day to 100 mg/kg/day.
The invention also provides an anti-tumor combined pharmaceutical composition, which comprises dronedarone hydrochloride and 5-fluorouracil. The dosage ratio of the dronedarone hydrochloride to the 5-fluorouracil is 1:1-1: 5.
The dronedarone hydrochloride combined with 5-fluorouracil can effectively inhibit the proliferation of human liver cancer cells HepG2, PLC/PRF/5 and Hep3B, can effectively inhibit the proliferation of human liver cancer cell strains HepG2, PLC/PRF/5 and Hep3B by singly using dronedarone hydrochloride, and can effectively inhibit the proliferation of human lung cancer cell lines SPC-A1 and A549 and mouse lung cancer cell lines Lewis by singly using dronedarone hydrochloride. The effect of the dronedarone hydrochloride and the 5-fluorouracil on inhibiting the cell proliferation of the human liver cancer cell Huh7 and the human lung cancer cell A459 is better than that of the dronedarone hydrochloride and the 5-fluorouracil which are used independently. The results show that the dronedarone hydrochloride combined antitumor drug has an inhibition effect on liver cancer cells and lung cancer cells. In addition, the combined use of dronedarone hydrochloride and 5-fluorouracil can obviously inhibit the growth of tumors in a mouse liver cancer transplantation tumor model, and the effect of inhibiting the growth of tumors in the mouse liver cancer transplantation tumor model is better than that of singly using 5-fluorouracil. The combined application of the antitumor drugs comprises but is not limited to 5-fluorouracil, and tumors comprise but is not limited to liver cancer and lung cancer.
The dronedarone hydrochloride and the 5-fluorouracil have obvious synergistic effect within the dosage proportion range of the invention, effectively improve the curative effect, have more obvious curative effect superposition compared with a single component or two components, and improve the killing property to tumor cells. Under the condition of ensuring the same treatment effect, the combined use of the dronedarone hydrochloride and the 5-fluorouracil can reduce the dosage of each other, thereby reducing the toxic and side effects. In addition, the joint use of the dronedarone hydrochloride and the 5-fluorouracil can save the cost and reduce the economic burden of patients, and the invention provides a new way for preventing and treating tumors and has wide application prospect in the field of medicine and pharmacology.
Drawings
FIG. 1 shows that dronedarone hydrochloride can inhibit the proliferation of human hepatoma cells HepG2, PLC/PRF/5 and Hep3B, and the cylindrical bars at all concentrations in the figure are HepG2, PLC/PRF/5 and Hep3B in sequence from left to right.
FIG. 2 shows that dronedarone hydrochloride can inhibit proliferation of human lung cancer cells SPC-A1 and A549 and mouse lung cancer cell Lewis, and the bars at each concentration are SPC-A1, A549 and Lewis from left to right.
FIG. 3 shows that dronedarone hydrochloride combined with 5-fluorouracil can inhibit the proliferation of human hepatoma cells HepG2, PLC/PRF/5 and Hep3B, and the columns at all concentrations in the figure are HepG2, PLC/PRF/5 and Hep3B in sequence from left to right.
FIG. 4 shows that dronedarone hydrochloride and 5-fluorouracil in different dosage ratios can inhibit the proliferation of human hepatoma cell Huh 7.
FIG. 5 shows that Dronedarone hydrochloride and 5-fluorouracil in different dosage ratios can inhibit the proliferation of human lung cancer cell A549.
FIG. 6 shows the effect of dronedarone hydrochloride and 5-fluorouracil in inhibiting tumor growth in a mouse model of liver cancer transplantable tumors.
Detailed Description
The beneficial effects of the drug of the present invention are further illustrated by the following experimental examples, but the present invention is not limited to these specific examples.
Experimental materials and instruments used in the examples
1. Experimental Material
1.1 Primary Agents and drugs
Dronedarone hydrochloride was purchased from huaxia reagent under lot number 2016031601, CAS number 141625-93-6; 5-Fluorouracil was purchased from Biyuntan corporation under the cat # ST 1060; DMEM high-glucose medium, purchased from Thermo Fisher, Inc., having a product number of 11965092; fetal bovine serum was purchased from Thermo Fisher corporation under the cat number 10099141; DMSO is available from Sigma under the designation D2650; the CCK-8 kit was purchased from doctor, cat # AR 1199.
1.2 Main instruments and consumables
CO of Thermo Fisher Co2Cell culture chambers (Heracell, 160i), Thermo Fisher Multifunction microplate reader (Varioskan LUX), cell culture flasks, 96-well cell culture plates were purchased from Wuxi Kansan Life technologies, Inc.
Example 1
Cell proliferation assay
Taking human liver cancer cells HepG2, PLC/PRF/5, Hep3B, human lung cancer cells SPC-A1 and A549 and mouse lung cancer cells Lewis which grow in logarithmic phase according to the proportion of 5 multiplied by 103Each cell/well was inoculated in 96-well culture medium containing 10% FBS in 5% CO in 100. mu.l of DMEM high-sugar medium per well2And cultured overnight in a cell culture box at 37 ℃. The final concentrations of dronedarone hydrochloride, 5-fluorouracil at 100. mu.M and dronedarone hydrochloride + 5-fluorouracil at 10. mu.M and dronedarone hydrochloride at 20. mu.M and 5-fluorouracil at 100. mu.M were added, respectively, and the control group was supplemented with DMSO at an equal volume, 100. mu.l DMEM high-glucose medium per well. Placing in 5% CO2And cultured in a cell culture box at 37 ℃ for 24 hours. Add 10. mu.l of CCK-8 solution to each well. Incubation was continued in the cell incubator for 0.5 hours. The absorbance was measured at 450 nm. Calculating the formula: cell survival rate ═ [ (experimental-blank)/(control-blank)]X 100%, assay well (cell-containing medium, CCK-8, test substance), control well (cell-containing medium, CCK-8, no test substance), blank well (medium without cells and test substance, CCK-8). And calculating and counting the survival rate of the cells of each group. The results show that the dronedarone hydrochloride concentration is between 5 and 20 mu M, can inhibit the proliferation of the human liver cancer cell HepG2, PLC/PRF/5, Hep3B, the human lung cancer cell lines SPC-A1 and A549 and the mouse lung cancer cell line Lewis, as shown in figure 1 and figure 2, and is dose-dependent. The inhibition rate of dronedarone hydrochloride and 5-fluorouracil on liver cancer cell inhibition is HepG2 (93.41%), PLC/PRF/5 (97.06%) and Hep3B (98.10%), as shown in figure 3. The combination of dronedarone hydrochloride and 5-fluorouracil is proved to be capable of effectively inhibiting the proliferation of the hepatoma cells.
Taking human liver cancer cell Huh7 and human lung cancer cell A549 growing in logarithmic phase, and adopting the formula of 5X 103Each cell/well was seeded in 96 wells for culture,each well was 100. mu.l of DMEM high-glucose medium containing 10% FBS in 5% CO2And cultured overnight in a cell culture box at 37 ℃. Dronedarone hydrochloride with a final concentration of 10. mu.M, 5-fluorouracil with a final concentration of 100. mu.M, dronedarone hydrochloride with a final concentration of 10. mu.M + 50. mu.M 5-fluorouracil, dronedarone hydrochloride with a final concentration of 10. mu.M + 40. mu.M 5-fluorouracil, dronedarone hydrochloride with a final concentration of 10. mu.M + 30. mu.M 5-fluorouracil, dronedarone hydrochloride with a final concentration of 10. mu.M + 20. mu.M 5-fluorouracil, dronedarone hydrochloride with a final concentration of 10. mu.M + 10. mu.M 5-fluorouracil, and DMSO with an equal volume of the control group was added. The results show that compared with the control group, 10 μ M dronedarone hydrochloride +50 μ M5-fluorouracil, 10 μ M dronedarone hydrochloride +40 μ M5-fluorouracil, 10 μ M dronedarone hydrochloride +30 μ M5-fluorouracil, 10 μ M dronedarone hydrochloride +20 μ M5-fluorouracil, 10 μ M dronedarone hydrochloride +10 μ M5-fluorouracil can inhibit the proliferation of human liver cancer cell Huh7 and human lung cancer cell a459, as shown in fig. 4 and 5, and the effect of inhibiting the proliferation of tumor cells is better than that of 10 μ M dronedarone hydrochloride and 100 μ M5-fluorouracil. The dosage ratio of the dronedarone hydrochloride to the 5-fluorouracil is preferably 1:5, 1:4, 1:3, 1:2 and 1:1.
Example 2
Mouse model for treating liver cancer transplantation tumor by dronedarone hydrochloride
According to the results of previous cell experiments, the dosage ratio of dronedarone hydrochloride to 5-fluorouracil is 1:1.5, and the tumor proliferation inhibition capability is detected in vivo. Taking human liver cancer cell Huh7 growing in logarithmic phase, preparing into cell suspension containing 1 × 10 per microliter4And (4) cells. Injecting 100 μ l of cell suspension into nude mice subcutaneously on the back, and randomly dividing the tumor-bearing mice into three groups when the tumor grows to 15 mm. One group is a solvent control group (physiological saline containing 5% DMSO), the other group is a dronedarone hydrochloride and 5-fluorouracil combined group (20mg/kg dronedarone hydrochloride, 30mg/kg 5-fluorouracil, dronedarone hydrochloride and 5-fluorouracil are dissolved in physiological saline containing 5% DMSO), and the other group is a 5-fluorouracil group (30mg/kg dronedarone hydrochloride is dissolved in physiological saline containing 5% DMSO). The treatment was performed by intraperitoneal injection of the drug on a daily basis, and tumor volumes were measured every other day. Tumor volume (long diameter × short diameter)/2. When the tumor tissue of the control group mice reaches 1000mm3At that time, the experiment was terminated and the tumor group was taken outThe tumors were weighed and photographed for recording. As shown in fig. 6. 30mg/kg of 5-fluorouracil alone can inhibit tumor volume, while the combined use of 20mg/kg of dronedarone hydrochloride and 30mg/kg of 5-fluorouracil can obviously inhibit tumor volume. The combination of dronedarone hydrochloride and 5-fluorouracil can effectively inhibit tumor volume and play an anti-tumor role. The dosage ratio of the dronedarone hydrochloride to the 5-fluorouracil is preferably 1:5-1: 1.
Claims (9)
1. The application of dronedarone hydrochloride and 5-fluorouracil in preparing antitumor drugs.
2. The use of dronedarone hydrochloride in combination with 5-fluorouracil according to claim 1, characterized in that: the anti-tumor medicine is a medicine for treating liver cancer and/or lung cancer.
3. The use of dronedarone hydrochloride in combination with 5-fluorouracil, as claimed in claim 1 or 2, in the preparation of antitumor drugs, characterized in that: the dosage form of the antitumor drug comprises any one pharmaceutically acceptable dosage form.
4. The use of dronedarone hydrochloride in combination with 5-fluorouracil, as claimed in claim 3, in the preparation of antitumor drugs, characterized in that: the dosage forms include oral dosage forms and injection dosage forms.
5. The use of dronedarone hydrochloride in combination with 5-fluorouracil, as claimed in claim 1 or 2, in the preparation of antitumor drugs, characterized in that: the two separate formulations of dronedarone hydrochloride and 5-fluorouracil are administered simultaneously or the two separate formulations are administered sequentially.
6. The use of dronedarone hydrochloride in combination with 5-fluorouracil according to claim 5, in the preparation of antitumor drugs, characterized in that: the dosage of the dronedarone hydrochloride is 20 mg/kg/day to 100 mg/kg/day, and the dosage of the 5-fluorouracil is 20 mg/kg/day to 100 mg/kg/day.
7. An anti-tumor pharmaceutical combination composition, characterized in that: comprises dronedarone hydrochloride and 5-fluorouracil.
8. The anti-tumor pharmaceutical combination composition according to claim 7, wherein: the tumors comprise liver cancer and lung cancer.
9. The anti-tumor pharmaceutical combination composition according to claim 7, wherein: the dosage ratio of the dronedarone hydrochloride to the 5-fluorouracil is 1:1-1: 5.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111393977.0A CN113925867A (en) | 2021-11-23 | 2021-11-23 | Application of dronedarone hydrochloride and 5-fluorouracil in preparation of antitumor drugs |
| PCT/CN2022/089862 WO2023092943A1 (en) | 2021-11-23 | 2022-04-28 | Use of dronedarone hydrochloride in combination with 5-fluorouracil in preparation of anti-tumor drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111393977.0A CN113925867A (en) | 2021-11-23 | 2021-11-23 | Application of dronedarone hydrochloride and 5-fluorouracil in preparation of antitumor drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113925867A true CN113925867A (en) | 2022-01-14 |
Family
ID=79287511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111393977.0A Pending CN113925867A (en) | 2021-11-23 | 2021-11-23 | Application of dronedarone hydrochloride and 5-fluorouracil in preparation of antitumor drugs |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN113925867A (en) |
| WO (1) | WO2023092943A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115974868A (en) * | 2022-11-07 | 2023-04-18 | 安徽理工大学 | Synthesis method of uracil derivative and potential application of uracil derivative in pulmonary fibrosis resistance |
| WO2023092943A1 (en) * | 2021-11-23 | 2023-06-01 | 中国人民解放军陆军军医大学第一附属医院 | Use of dronedarone hydrochloride in combination with 5-fluorouracil in preparation of anti-tumor drug |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101642451A (en) * | 2008-08-08 | 2010-02-10 | 上海安普生物科技有限公司 | New application of amiodarone and derivatives thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105193810B (en) * | 2015-10-30 | 2017-11-24 | 浙江康佰裕生物科技有限公司 | 5 fluorouracil compositions and its application in antitumor injection is prepared |
| CN110384688B (en) * | 2019-08-14 | 2023-03-17 | 新疆农业大学 | 5-fluorouracil oral colon-specific drug delivery system and preparation method thereof |
| CN112137999A (en) * | 2020-09-30 | 2020-12-29 | 郑州大学 | Application of dronedarone hydrochloride in preparation of medicine for resisting digestive tract tumor |
| CN113925867A (en) * | 2021-11-23 | 2022-01-14 | 中国人民解放军陆军军医大学第一附属医院 | Application of dronedarone hydrochloride and 5-fluorouracil in preparation of antitumor drugs |
-
2021
- 2021-11-23 CN CN202111393977.0A patent/CN113925867A/en active Pending
-
2022
- 2022-04-28 WO PCT/CN2022/089862 patent/WO2023092943A1/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101642451A (en) * | 2008-08-08 | 2010-02-10 | 上海安普生物科技有限公司 | New application of amiodarone and derivatives thereof |
Non-Patent Citations (1)
| Title |
|---|
| ANEESH KARKHANIS ET AL: "Inhibition and inactivation of human CYP2J2: Implications in cardiac pathophysiology and opportunities in cancer therapy.", 《BIOCHEMICAL PHARMACOLOGY》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023092943A1 (en) * | 2021-11-23 | 2023-06-01 | 中国人民解放军陆军军医大学第一附属医院 | Use of dronedarone hydrochloride in combination with 5-fluorouracil in preparation of anti-tumor drug |
| CN115974868A (en) * | 2022-11-07 | 2023-04-18 | 安徽理工大学 | Synthesis method of uracil derivative and potential application of uracil derivative in pulmonary fibrosis resistance |
| CN115974868B (en) * | 2022-11-07 | 2024-04-12 | 安徽理工大学 | Synthesis method of uracil derivative and potential application of uracil derivative in aspect of resisting pulmonary fibrosis |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023092943A1 (en) | 2023-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2017162108A1 (en) | Pillararene complex, preparation method, pharmaceutical composition and use thereof | |
| WO2019174571A1 (en) | Pharmaceutical composition and use thereof in preparing drug for treating tumor multi-drug resistance | |
| CN101273989B (en) | Berbamine derivative and application of salt thereof | |
| WO2023092943A1 (en) | Use of dronedarone hydrochloride in combination with 5-fluorouracil in preparation of anti-tumor drug | |
| CN102552908B (en) | Pharmaceutical composition containing artemisinin, artemisinin derivatives and Bcl-2 inhibitor and application thereof | |
| WO2019228524A1 (en) | Pharmaceutical composition for treating kidney cancer and application thereof | |
| CN111346081A (en) | New use of pharmaceutical composition comprising n-pentanoic acid, indolpropanic acid and sodium n-butyrate | |
| WO2019214723A1 (en) | Application of chlorogenic acid and compositions thereof in preparation of drugs for treating squamous cell carcinoma | |
| WO2013071696A1 (en) | Use of five normal bases in humans for preparation of tumour drugs | |
| CN112494500B (en) | Application of Rudesiwei in preparing cardiotoxic medicine for treating anti-tumor medicine | |
| CN102218140B (en) | Tumor resistance effect of medicine combination of salvianolic acid B and coxib medicaments | |
| CN108295085B (en) | Application of protodioscin in preparation of drug-resistant osteosarcoma drug | |
| CN109793727A (en) | A kind of pharmaceutical composition and its application of effective anti-malignant tumor | |
| CN111821303B (en) | Application of vortioxetine and salts thereof in preparation of antitumor drugs | |
| US9943560B2 (en) | Medical compositions containing liquorice extracts with synergistic effect | |
| CN111905102A (en) | Use of EZH2 inhibitors for the treatment of gliomas | |
| WO2019037671A1 (en) | Medicine for combined use in cancer treatment | |
| CN111803482B (en) | Application of cornu Cervi Pantotrichum monomer in preparing medicine for inhibiting breast tumor bone metastasis and medicine | |
| CN111728960B (en) | Application of bisoprolol fumarate and docetaxel in preparation of antitumor drugs | |
| CN116549478B (en) | Pharmaceutical composition and preparation method and application thereof | |
| CN117731654B (en) | New application of JJH201601 in treatment of primary glioma and recurrent glioma | |
| CN111632146B (en) | Application of OAT inhibitor and oncolytic virus in preparation of antitumor drugs | |
| WO2010101353A2 (en) | Composition containing human serum albumin-timp-2 fusion protein and anti-cancer drug for preventing or treating cancer | |
| CN109846876B (en) | Application of lignan compound in resisting tumor and preparation of medicine thereof | |
| CN102440994A (en) | Application of ganoderic acid G as immune synergist and super-antigen dependent therapeutic medicine in tumour treatments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |